Interaction between purinergic signalling and purinergic modulators with skin wound repair effectors: a systematic review of preclinical in vivo models.
Silvânia Mól Pelinsari, Reggiani Vilela Goncalves, Patricia da Silva Mattosinhos et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review examined the effects of purinergic modulators on skin wound healing in preclinical animal models. The review identified 12 studies and found that purinergic agonists significantly enhanced wound healing processes, including fibroblast proliferation and angiogenesis, while antagonists delayed wound closure and exacerbated inflammation. Agonists activated key signaling pathways, contributing to improved tissue repair.
Key findings
- Purinergic agonists stimulated wound contraction and fibroblast proliferation, enhancing healing.
- Topical or oral administration of agonists activated Nrf2, MAPK, and ERK/CREB pathways.
- Purinergic antagonists delayed wound closure and impaired angiogenesis and collagenogenesis.
- Genetic knockout of purinergic receptors aggravated inflammation and oxidative damage.
Why it matters
Understanding the role of purinergic signaling in wound healing can inform therapeutic strategies. Enhancing tissue repair through purinergic agonists may offer new avenues for improving patient outcomes in skin injuries.